The Education Session “Next-Generation Diagnostics Beyond Tissue” on June 4* promises to provide an in-depth look at the novel innovations in noninvasive cancer molecular diagnostic platforms as well as their potential and challenges.
After two recent clinical trials provided long-awaited new information on the role of lymph node management in patients with melanoma, a panel was formed to update the 2012 ASCO-Society of Surgical Oncology (SSO) guidelines for sentinel lymph node (SLN) biopsy.
Data presented during the 2012 ASCO Annual Meeting demonstrated the potential of anti–PD-1 and anti–PD-L1 therapy for multiple cancers and introduced groundbreaking change in oncology research and treatment.
The treatment paradigm of breast cancer has celebrated the successes of targeted therapy for decades. Currently, the hormone receptor and HER2 statuses of a breast tumor continue to drive the selection of therapy for patients with early-stage breast cancer and metastatic breast cancer (mBC).
Rare genitourinary neoplasms encompass diseases of the kidney, bladder, prostate, and penile tract that are of uncommon histology. These entities often pose a major diagnostic and treatment dilemma to the treating physician.
Evidence from multiple positive trials, support from literature reviews and editorials, and the endorsements of professional societies and funding agencies all promote the use of patient-reported outcomes (PROs) in clinical cancer care.
Cannabis use in Western medicine was initially popularized by Irish physician William B. O’Shaughnessy in 1840. It was included in the U.S. Pharmacopeia shortly afterward and was often prescribed for rheumatism, cholera, tetanus, rabies, and labor pain.
Enrique Soto, MD, of the Salvador Zubiran National Institute of Medical Science and Nutrition, in Mexico City, grew up to the sound of seismic alarms. Mexico City is located on a fault line, and Dr. Soto was no stranger to feeling the earth shake beneath his feet.